Compare Genuine Parts Company (GPC) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs 10X Genomics Inc — how do they compare? Genuine Parts Company trades at $127.56 (market cap $17.29B), while 10X Genomics Inc trades at $79.65 (market cap $9.92B). The key difference: Genuine Parts Company is the larger of the two by market cap, and Genuine Parts Company pays a 3.39% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and 10X Genomics Inc for 92 Days on average.
| GPC | TXG | |
|---|---|---|
Market Cap | $17.29B | $9.92B |
Volume | 900,870 | 9,372,166 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $97.74 |
52-Week Low | $92.47 | $11.48 |
Typical Hold Time | 75 Days | 92 Days |
Enterprise Value | $23.38B | $9.44B |
Dividend Yield | 3.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $128.17, up 0.62% today, with a bearish technical signal but neutral oscillators. The company reported mixed earnings, missing in Q4 2025 but beating in Q1 and Q2 2026, with Q3 2026 results due October 20, 2026. Revenue grew to $24.3B in 2025, but net income margin fell sharply to 0.13%. Analyst consensus is a Buy with a $145.75 price target, and the upcoming spinoff of the industrial unit Motion in Q1 2027 is a key catalyst.
The outlook is cautiously optimistic due to the spinoff potential and dividend stability, but risks include declining profitability, high P/E ratio of 501.64, and bearish technical trends. Investors should weigh the long-term benefits of the separation against near-term margin pressures and debt levels rising to 23.08% of assets in 2025.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
